Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.46 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484827 | 1.00 | CHRNA7 (0.49) | CHRNA7KCNH2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2484828 | 1.00 | CHRNA7 (0.49) | CHRNA7KCNH2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL746332 | 0.92 | CHRNA7 (0.48) | CHRNA7KCNH2CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL746978 | 0.91 | CHRNA7 (0.47) | CHRNA7KCNH2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL744535 | 0.88 | CHRNA7 (0.41) | CHRNA7KCNH2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL746345 | 0.87 | PRKCZ (0.43) | SLC6A2SLC6A3 | |
| SCHEMBL744687 | 0.86 | CHRNA7 (0.49) | CHRNA7KCNH2SLC6A2SLC6A3 | |
| SCHEMBL743968 | 0.86 | CHRNA7 (0.53) | CHRNA7KCNH2CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL2481429 | 0.85 | CHRNA7 (0.52) | CHRNA7KCNH2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL748372 | 0.84 | KCNH2 (0.53) | CHRNA7KCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | claimed |
| EP-2945626-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | Novartis AG (CH) | 2015-11-25 | — | — | EP | claimed |
| US-20150313884-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS PHARMA AG (CH) | 2015-11-05 | — | — | US | claimed |
| US-8940762-B2 | Methods for treating pain | ABBVIE INC. (US) | 2015-01-27 | — | — | US | claimed |
| WO-2014111751-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | claimed |
| EP-2431368-A1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | Abbott Laboratories (US) | 2012-03-21 | — | — | EP | claimed |
| EP-2018380-B1 | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2011090669-A1 | METHODS FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2011-07-28 | — | — | WO | claimed |
| US-20110178121-A1 | Methods for Treating Pain | ABBOTT LABORATORIES (US) | 2011-07-21 | — | — | US | claimed |
| US-7872017-B2 | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | claimed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | claimed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2022-10-06 | — | — | US | disclosed |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20110178121-A1 | Methods for Treating Pain | ABBOTT LABORATORIES (US) | 2011-07-21 | — | — | US | disclosed |
| US-7872017-B2 | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, BMP2, ALKBH2 | CHRNA7 2776/4885KCNH2 708/4885CHRNB2 2585/4885 |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | MALT1, BMP2, ALKBH2 | CHRNA7 2776/4885KCNH2 708/4885CHRNB2 2585/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885KCNH2 2839/4885CHRNB2 9/4885 |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA4 | CHRNA7 1/4885KCNH2 745/4885CHRNB2 16/4885 |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885KCNH2 2839/4885CHRNB2 9/4885 |
| US-20110178121-A1 | Methods for Treating Pain | CHRNA7, CHRNA3, CHRNA5 | CHRNA7 1/4885KCNH2 183/4885CHRNB2 12/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885KCNH2 2953/4885CHRNB2 9/4885 |
| US-20150313884-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885KCNH2 472/4885CHRNB2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.